First-line pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma: Health-related quality of life from the randomized phase III KEYNOTE-859 trial.
- DOI
- 10.1016/j.ejca.2025.115807
- Published
- 2025 Dec 9
- Container
- European journal of cancer (Oxford, England : 1990)
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.ejca.2025.115807,
title = {First-line pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma: Health-related quality of life from the randomized phase III KEYNOTE-859 trial.},
author = {Lowery MA and Wyrwicz LS and Oh DY and Shiu KK and Yañez P and Bai Y and Ryu MH and Lee J and Rivera F and Alves GV and Garrido M and Fernández MG and Li J and Çil T and Cruz FM and Qin S and Guan Y and Valderrama A and Bordia S and Rha SY},
year = {2025},
journal = {European journal of cancer (Oxford, England : 1990)},
doi = {10.1016/j.ejca.2025.115807},
url = {https://doi.org/10.1016/j.ejca.2025.115807}
}RIS
TY - JOUR TI - First-line pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma: Health-related quality of life from the randomized phase III KEYNOTE-859 trial. AU - Lowery MA AU - Wyrwicz LS AU - Oh DY AU - Shiu KK AU - Yañez P AU - Bai Y AU - Ryu MH AU - Lee J AU - Rivera F AU - Alves GV AU - Garrido M AU - Fernández MG AU - Li J AU - Çil T AU - Cruz FM AU - Qin S AU - Guan Y AU - Valderrama A AU - Bordia S AU - Rha SY PY - 2025 JO - European journal of cancer (Oxford, England : 1990) DO - 10.1016/j.ejca.2025.115807 UR - https://doi.org/10.1016/j.ejca.2025.115807 ER -
APA
MA, L., LS, W., DY, O., KK, S., P, Y., Y, B., MH, R., J, L., F, R., GV, A., M, G., MG, F., J, L., T, Ç., FM, C., S, Q., Y, G., A, V., S, B., & SY, R. (2025). First-line pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma: Health-related quality of life from the randomized phase III KEYNOTE-859 trial.. European journal of cancer (Oxford, England : 1990). https://doi.org/10.1016/j.ejca.2025.115807
Source records
- pubmed · retrieved 2026-09-26T06:20:51.200Z